From Gene-Edited Embryos to Covid: China Faces Regulatory and Ethical Challenges
By Yuting Zhu and Jonathan D. Moreno,
The Hastings Center
| 07. 28. 2022
In early April, He Jiankui, the Chinese scientist who used gene-editing technology on human embryos born in 2018, was released from his three-year prison sentence, imposed after a Shenzhen District Court convicted him of “illegal medical practice.” He and two accomplices were banned from conducting any work related to assisted reproductive technology, applying for administrative permits for research on human genetic resources, and from applying for research funds.
The He Jiankui affair and, little more than a year later, the Covid pandemic have focused attention in China on ethical governance of research and medical practice. Over the last two years, China has updated some regulations on human genetic engineering and assisted reproduction and established a national committee to guide and supervise bioethics nationwide. But there are legal gaps in some of the regulations and tension between competing values: the desire to encourage new research and to potentially inhibit it by imposing stricter ethics regulations.
An example of this tension came out in public expression over He Jiankui. Ever since his arrest there have been occasional comments on Chinese social media...
Related Articles
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Judith Levine, The Intercept | 04.04.2024
WHEN THE ALABAMA Supreme Court ruled that fertilized embryos were “extrauterine children,” it did more than imperil the future of in vitro fertilization in Alabama and, potentially, the U.S. The ruling, on the claimed “wrongful death” of frozen embryos...